Takashi Kagari
Vice President Daiichi Sankyo
Dr. Kagari has more than 25 years of pharmaceutical industry experience focusing on drug discovery research for immunology and oncology. He joined the former Sankyo (now Daiichi Sankyo Co., Ltd.) and started his career as an immunologist. Following the completion of his PhD at Osaka University, he did his post-doctoral research at UCSF and returned to the company. He is currently responsible for leading the strategy and execution of oncology discovery research of antibody-drug conjugate (ADC) for targeted cancer therapy at Daiichi Sankyo.
Seminars
Tuesday 13th October 2026
Panel Discussion: Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
8:00 am
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
